Reading this on a mobile device? Try our optimized mobile version here:

December 14, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Expert: Whole genome sequencing does not violate gene patents
    Some academics, ethicists and researchers worry that whole genome sequencing will violate patents on genes if the Supreme Court upholds Myriad Genetics' patents on two genes associated with breast cancer. However, the patentee has exclusive rights only to specific applications involving the isolated gene and does not own the gene itself as it exists in the genome, writes Harvard health law fellow Nicholson Price. Moreover, any infringement that does take place likely can be compensated through small royalty payments and any gene patents will eventually expire, he notes. Bio-IT World (12/10) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Milo wins orphan status for muscular dystrophy drug
    The FDA granted orphan-drug status to Milo Biotechnology's experimental gene therapy AAV1-FS344 as a treatment for Becker and Duchenne muscular dystrophy. The designation qualifies Milo for tax credits and seven years of marketing exclusivity. (12/12) LinkedInFacebookTwitterEmail this Story
  • Bayer submits prostate cancer drug for European approval
    Bayer submitted an application to the European Medicines Agency seeking approval to market Alpharadin, developed by Algeta, as a treatment for castration-resistant prostate cancer with bone metastases. Alpharadin is the first in a class of drugs based on radium-223. The filing was devloped from late-stage trial data indicating that Alpharadin significantly improved overall survival and risk of death compared with placebo. PharmaTimes (U.K.) (12/13) LinkedInFacebookTwitterEmail this Story
Top 5 Trends for Nutraceuticals in 2018
Business is booming for nutraceuticals as consumers turn to vitamins, minerals, herbs, innovative foods and other natural products to improve their health. The industry has expanded its focus to not just provide natural, clean products but also innovative, high-quality ones. The five biggest trends for 2018 reflect this, bringing new steps and creativity to the product development process. Download the whitepaper
  Company & Financial News 
  • Roche plans $259M expansion at German site
    Roche Holding plans to invest around $259 million to build a new manufacturing plant at its Penzberg biotechnology site near Munich in response to sustained global demand for its diagnostic test and control reagents. The plant, which will be called Diagnostics Operations Complex II, could begin production by the end of 2014. Genetic Engineering & Biotechnology News (12/12) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • Cellulosic ethanol could hit the market in 2013
    After years in the pre-commercial stage, cellulosic ethanol is expected to finally hit the market in 2013, executives said. "It's been an incredible journey and one that we knew would require thinking differently," said Jim Collins, president of DuPont Industrial BioSciences, which is developing a commercial cellulosic plant in Nevada, Iowa. The upcoming cellulosic ethanol plants will be good for rural communities, but their long-term prospects are still uncertain given the boom in domestic natural gas production, said Dave Swenson, an economist at Iowa State University. KBIA-FM (Columbia, Mo.) (12/13) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

The best preparation for tomorrow is to do today's work superbly well."
--William Osler,
Canadian physician

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information